WO1996040096B1 - INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES - Google Patents
INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANESInfo
- Publication number
- WO1996040096B1 WO1996040096B1 PCT/US1996/009832 US9609832W WO9640096B1 WO 1996040096 B1 WO1996040096 B1 WO 1996040096B1 US 9609832 W US9609832 W US 9609832W WO 9640096 B1 WO9640096 B1 WO 9640096B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dibenzyl
- cancer
- diaminoalkanes
- pharmaceutically
- group
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims abstract 12
- 230000002401 inhibitory effect Effects 0.000 title claims abstract 5
- 230000010261 cell growth Effects 0.000 title abstract 3
- 206010027476 Metastasis Diseases 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- IXBTYWVCTCYLJR-UHFFFAOYSA-N N,N'-dibenzylbutane-1,4-diamine Chemical compound C=1C=CC=CC=1CNCCCCNCC1=CC=CC=C1 IXBTYWVCTCYLJR-UHFFFAOYSA-N 0.000 claims 2
- IMWDTSQNQPMQDP-UHFFFAOYSA-N N,N'-dibenzylpentane-1,5-diamine Chemical compound C=1C=CC=CC=1CNCCCCCNCC1=CC=CC=C1 IMWDTSQNQPMQDP-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N Putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 abstract 2
- 239000005700 Putrescine Substances 0.000 abstract 1
Abstract
The present invention relates to the inhibition of cancer cell growth, proliferation, and metastasis by contacting cells with an N,N'-dibenzyl-α,φ-diaminoalkane, a derivative of naturally-occurring putrescine. More specifically, the present invention relates to the treatment of cancer in humans by administration of a cancer cell growth-inhibiting amount of an N,N'-dibenzyl-α,φ-diaminoalkane to a human cancer patient,
Claims
AMENDED CLAIMS
[received by the International Bureau on 17 December 1996 (17.12.96); original claims 1-5 and 7-18 cancelled; original claims 6 and 19-21 unchanged; new claims 22-25 added (2 pages)]
6. A method of inhibiting growth of cancer cells comprising contacting the cells with an effective growth-inhibiting amount of a compound selected from the group consisting of
HsC6-CH2-NH-(CH2)x-NH-CH2-C6Hj wherein X is an integer of from 3-8, pharmaceutically-suitable salts thereof, and mixtures thereof.
19. A pharmaceu tical unit dosage form comprising an amount of a compound selected from the group consisting of linear C2-Cι0 N,N'-dibenzyl-α,ω- diaminoalkanes, branched C2-C10 N,N'-dibenzyl-α,ω-diaminoalkanes, pharmaceutically-s litable salts thereof, and mixtures thereof; in combination with a pharmaceutically-acceptable carrier, wherein said amount is effective to inhibit growth of cancer cells within a human cancer patient following administration thereto.
20. The pharmaceutical unit dosage form according to Claim 19, wherein, said compound is N,N'-dibenzylputrescine.
21. The pharmaceutical unit dosage form according to Claim 19, wherein said compound is N,N'-dibenzylcadaverine.
22. Compounds selected from the group consisting of linear C2-C10 N,N'- dibenzyl-α,amino-diaminoalkanes, branched C2-C10 N,N'-dibenzyl-α,amino- diaminoalkanes, pharmaceutically-suitable salts thereof, and mixtures thereof, for use in the treatment of cancer.
30
23. Compounds for use in the treatment of cancer according to claim 22, wherein the compounds are selected from the group consisting of:
wherein X is an integer of from 3-8, pharmaceutically suitable salts thereof, and mixtures thereof.
24. Compounds for use in the treatment of cancer according to claim 22 or 23, wherein the compound is selected from the group consisting of N,N'- dibenzylputrescine and N,N'-dibenzylcadaverine.
25. Use of one or more compounds according to any one of claims 22, 23, or 24, for the manufacture of a medicament for the treatment of cancer in mammalian subjects.
31
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU63819/96A AU6381996A (en) | 1995-06-07 | 1996-06-07 | Inhibition of cancer cell growth, proliferation and metastas is using n,n'-dibenzyl-alpha,omega-diaminoalkanes |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/472,431 | 1995-06-07 | ||
| US08/472,431 US5677350A (en) | 1995-06-07 | 1995-06-07 | Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996040096A1 WO1996040096A1 (en) | 1996-12-19 |
| WO1996040096B1 true WO1996040096B1 (en) | 1997-01-23 |
Family
ID=23875484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/009832 WO1996040096A1 (en) | 1995-06-07 | 1996-06-07 | INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5677350A (en) |
| AU (1) | AU6381996A (en) |
| WO (1) | WO1996040096A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087648B1 (en) * | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US8198334B2 (en) * | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| EP1159261B1 (en) * | 1999-02-05 | 2005-11-02 | Oridigm Corporation | Antizyme modulators and their use |
| NZ515140A (en) * | 1999-04-30 | 2003-07-25 | Slil Biomedical Corp | Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others |
| US6482943B1 (en) * | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
| CA2368801A1 (en) * | 1999-04-30 | 2000-11-09 | Slil Biomedical Corporation | Conjugates as therapies for cancer and prostate diseases |
| US6649587B1 (en) | 1999-04-30 | 2003-11-18 | Slil Biomedical Corporation | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases |
| US6872852B2 (en) * | 2000-03-24 | 2005-03-29 | Mediquest Therapeutics, Inc. | Polyamine analogues as cytotoxic agents |
| WO2002091989A2 (en) | 2000-11-08 | 2002-11-21 | Slil Biomedical Corporation | Antiviral therapies using polyamine or polyamine analog-amino acid conjugates |
| WO2003013245A1 (en) * | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| AU2002364539A1 (en) | 2001-12-07 | 2003-06-23 | Cellgate, Inc. | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor |
| KR20040091014A (en) * | 2002-02-07 | 2004-10-27 | 위스콘신 얼럼나이 리서어치 화운데이션 | Polyamine Compounds and Compositions for Use in Conjunction with Cancer Therapy |
| JP2005533820A (en) * | 2002-06-26 | 2005-11-10 | セルゲイト， インコーポレイテッド | Porphyrin-polyamine conjugates for cancer treatment |
| US20040192665A1 (en) * | 2002-08-02 | 2004-09-30 | Slil Biomedical Corporation | Conjugates of porphyrin compounds with chemotherapeutic agents |
| US8968702B2 (en) * | 2006-03-30 | 2015-03-03 | Duke University | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4413141A (en) * | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4330559A (en) * | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| US4499072A (en) * | 1982-11-29 | 1985-02-12 | Merrell Dow Pharmaceuticals Inc. | Process for treating diseases with ODC inhibitors |
| US4914240A (en) * | 1985-08-21 | 1990-04-03 | Merrell Dow Pharmaceuticals Inc. | Gem-dihalo-1, 8-diamino-4-aza-octanes |
| US4925835A (en) * | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
| ATE77367T1 (en) * | 1988-02-05 | 1992-07-15 | Merrell Dow Pharma | 5-SUBSTITUTED ORNITHINE DERIVATIVES. |
| US5002870A (en) * | 1988-06-07 | 1991-03-26 | California Institute For Medical Research | Plastin isoforms and their use |
| US4935449A (en) * | 1988-08-04 | 1990-06-19 | Merrell Dow Pharmaceuticals Inc. | N-2,3-butadienyl tri- and tetraaminoalkane derivatives |
| US5344846A (en) * | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
-
1995
- 1995-06-07 US US08/472,431 patent/US5677350A/en not_active Expired - Fee Related
-
1996
- 1996-06-07 WO PCT/US1996/009832 patent/WO1996040096A1/en active Search and Examination
- 1996-06-07 AU AU63819/96A patent/AU6381996A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996040096B1 (en) | INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES | |
| BR9609063A (en) | Dinucleotides useful for the treatment of lung diseases | |
| IT1178154B (en) | THERAPY USE OF METHYLOL TRANSFER COMPOUNDS, RELATED PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR PREPARING THESE | |
| NO852872L (en) | PROCEDURE FOR THE PREPARATION OF NEW TETRAPYROLS. | |
| ES8703860A1 (en) | Aminoalkylphenoxy derivatives. | |
| CA2333965A1 (en) | Method of enhancing lysosomal .alpha.-galactosidase a | |
| KR900001677A (en) | Biaryl compounds | |
| CA2108903A1 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| RU95105973A (en) | Method of toxoplasmosis severity decrease, pharmaceutical composition, use of rifamycin derivatives for preparing the medicinal preparations for toxoplasmosis treatment | |
| US4182752A (en) | Neocarzinostatin derivatives and a process for producing the same | |
| KR870005004A (en) | Macrolide Antibiotic Derivatives | |
| EP0376899A3 (en) | Use of L-carnitine derivatives for the manufacture of a medicament for the therapeutical treatment of peripheral neuropathies | |
| CA2334119A1 (en) | Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase | |
| WO1990014831A3 (en) | 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition | |
| DK0531413T3 (en) | An antiviral preparation containing prostratin | |
| KR920004387A (en) | 4-substituted dihydropyrido [4,3-d] pyrimidines as topical anti-inflammatory agents for the treatment of analgesics and skin diseases | |
| US3326761A (en) | 6-demethyl-6-deoxytetracycline, anti-tumor antibiotic | |
| KR880003973A (en) | Pharmacologically active compounds and uses | |
| NO974651L (en) | Biologically active ureido derivatives useful in the treatment of multiple sclerosis | |
| EP0670165B1 (en) | Use of seminal ribonuclease as antimetastatic compound | |
| NO164170C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1-BENZHYDRYL-4-CINNAMYL-PIPERAZINE DERIVATIVES. | |
| ES8506756A1 (en) | Aphidicolane derivatives, their preparation and pharmaceutical compositions comprising them. | |
| KR920011486A (en) | Antitumor agents | |
| JPS63146839A (en) | Carcinostatic agent containing pterosin | |
| JPS61130218A (en) | Antitumor agent |